Fulcrum Therapeutics Inc.

NASDAQ: FULC · Real-Time Price · USD
6.81
0.21 (3.18%)
At close: Aug 15, 2025, 3:59 PM
6.82
0.15%
After-hours: Aug 15, 2025, 04:10 PM EDT

Fulcrum Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021
Revenue
n/a 80M 80M 80.87M 81.63M 2.51M 2.81M 2.62M 3.04M 4.04M 6.34M 10.71M 14.47M 16.97M 19.16M 18.33M 15.24M
Cost of Revenue
n/a 17.26M 17.74M 18.25M 18.75M 2.09M 2.17M 2.26M 2.36M 26.78M 26.75M 26.78M 43.25M 35.61M 51.41M 69.66M 67.44M
Gross Profit
n/a 62.74M 62.26M 62.62M 62.88M 423K 631K 362K 686K -22.73M -20.4M -16.06M -28.79M -18.65M -32.25M -51.33M -52.2M
Operating Income
-84.77M -12.47M -21.9M -30.46M -32.77M -112.56M -110.66M -110.64M -107.56M -114.5M -112.56M -108.15M -104.56M -90.01M -81.05M -75.28M -73.62M
Interest Income
n/a n/a n/a n/a n/a 3.51M 3.51M 3.51M 3.51M n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-73.22M -510K -9.72M -17.91M -20.23M -99.43M -97.33M -98.71M -98.44M -108.72M -109.87M -107.22M -104.2M -89.78M -80.85M -75.08M -73.33M
Net Income
-73.22M -510K -9.72M -17.91M -20.23M -99.43M -94.17M -93.05M -93.08M -103.37M -107.61M -107.46M -104.13M -89.71M -80.85M -75.08M -73.33M
Selling & General & Admin
29.97M 33.39M 36.45M 38.09M 39.63M 39.7M 41.16M 41.93M 41.68M 42.45M 41.69M 41.27M 40.19M 35.78M 30.52M 26.68M 23.36M
Research & Development
52.37M 56.65M 62.54M 70.19M 73.79M 74.38M 71.8M 71.37M 68.5M 75.67M 76.78M 77.13M 78.84M 71.2M 69.7M 66.93M 65.5M
Other Expenses
2.06M 2.06M 2.06M 2.06M 3.42M 6.93M 10.09M 11.93M 9.13M 5.78M 2.69M 927K 364K 233K 207K 199K 287K
Operating Expenses
84.77M 92.47M 101.42M 110.34M 113.42M 114.08M 112.96M 113.3M 110.18M 118.12M 118.48M 118.4M 119.03M 106.97M 100.22M 93.61M 88.86M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a -508K -508K -508K -508K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
64.96M 92.47M 101.9M 111.33M 114.4M 115.07M 113.47M 113.3M 110.18M 118.12M 118.48M 118.4M 119.03M 106.97M 100.22M 93.61M 88.86M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -3.16M -5.67M -5.35M -5.38M -2.29M 219K -75K -79K -9K -9K -28K
Shares Outstanding (Basic)
62.54M 62.48M 53.95M 62.41M 62.2M 61.98M 61.87M 61.82M 61.79M 59.72M 52.08M 46.21M 40.89M 40.64M 40.58M 36.61M 32.64M
Shares Outstanding (Diluted)
62.54M 62.48M 53.95M 62.41M 63.59M 61.98M 61.87M 61.82M 61.79M 59.72M 52.08M 46.21M 40.89M 40.64M 40.58M 36.61M 32.64M
EPS (Basic)
-1.22 -0.05 -0.2 -0.29 -0.33 -1.6 -1.53 -1.58 -1.71 -2.16 -2.44 -2.57 -2.62 -2.39 -2.29 -2.35 -2.48
EPS (Diluted)
-1.22 -0.07 -0.22 -0.31 -0.35 -1.6 -1.53 -1.58 -1.71 -2.16 -2.44 -2.57 -2.62 -2.39 -2.29 -2.35 -2.48
EBITDA
-81.62M -6M -15.3M -23.72M -27.94M -110.47M -108.49M -108.43M -104.8M -111.63M -109.72M -105.24M -102.11M -87.56M -78.54M -72.66M -71.05M
EBIT
-80.19M -7.49M -16.92M -25.48M -29.86M -112.56M -110.66M -110.68M -107.13M -114.08M -112.13M -107.68M -104.56M -90.01M -81.05M -75.28M -73.62M
Depreciation & Amortization
1.09M 1.09M 1.22M 1.36M 1.49M 2.09M 2.17M 2.26M 2.36M 2.46M 2.43M 2.46M 2.46M 2.46M 2.52M 2.64M 2.59M